^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Mvasi (bevacizumab-awwb) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    01/15/2018
    Excerpt:
    Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of… Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment
    Secondary therapy:
    carboplatin + paclitaxel